Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 2
1946 2
1947 3
1948 2
1949 2
1953 3
1955 2
1957 2
1958 2
1960 1
1961 2
1962 4
1963 4
1964 3
1965 7
1966 13
1967 13
1968 12
1969 15
1970 17
1971 16
1972 30
1973 27
1974 22
1975 26
1976 31
1977 26
1978 24
1979 14
1980 22
1981 28
1982 31
1983 35
1984 40
1985 61
1986 61
1987 55
1988 93
1989 121
1990 181
1991 237
1992 281
1993 353
1994 262
1995 224
1996 211
1997 234
1998 293
1999 302
2000 318
2001 284
2002 258
2003 276
2004 270
2005 311
2006 314
2007 342
2008 378
2009 397
2010 388
2011 425
2012 419
2013 433
2014 407
2015 307
2016 225
2017 224
2018 242
2019 143
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

9,180 results
Results by year
Filters applied: . Clear all
Page 1
Iron and ferroptosis: A still ill-defined liaison.
Doll S, Conrad M. Doll S, et al. IUBMB Life. 2017 Jun;69(6):423-434. doi: 10.1002/iub.1616. Epub 2017 Mar 9. IUBMB Life. 2017. PMID: 28276141 Free article. Review.
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Loriot Y, et al. N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323. N Engl J Med. 2019. PMID: 31340094 Clinical Trial.
Targeting FGFR pathway in breast cancer.
Perez-Garcia J, Muñoz-Couselo E, Soberino J, Racca F, Cortes J. Perez-Garcia J, et al. Breast. 2018 Feb;37:126-133. doi: 10.1016/j.breast.2017.10.014. Epub 2017 Nov 20. Breast. 2018. PMID: 29156384 Review.
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL. Formisano L, et al. Nat Commun. 2019 Mar 26;10(1):1373. doi: 10.1038/s41467-019-09068-2. Nat Commun. 2019. PMID: 30914635 Free PMC article.
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV. Perera TPS, et al. Mol Cancer Ther. 2017 Jun;16(6):1010-1020. doi: 10.1158/1535-7163.MCT-16-0589. Epub 2017 Mar 24. Mol Cancer Ther. 2017. PMID: 28341788 Free article.
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Zeuzem S, et al. N Engl J Med. 2018 Jan 25;378(4):354-369. doi: 10.1056/NEJMoa1702417. N Engl J Med. 2018. PMID: 29365309 Free article. Clinical Trial.
Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial.
Reese PP, Abt PL, Blumberg EA, Van Deerlin VM, Bloom RD, Potluri VS, Levine M, Porrett P, Sawinski D, Nazarian SM, Naji A, Hasz R, Suplee L, Trofe-Clark J, Sicilia A, McCauley M, Gentile C, Smith J, Niknam BA, Bleicher M, Reddy KR, Goldberg DS. Reese PP, et al. Ann Intern Med. 2018 Sep 4;169(5):273-281. doi: 10.7326/M18-0749. Epub 2018 Aug 7. Ann Intern Med. 2018. PMID: 30083748 Clinical Trial.
Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
Nishina T, Takahashi S, Iwasawa R, Noguchi H, Aoki M, Doi T. Nishina T, et al. Invest New Drugs. 2018 Jun;36(3):424-434. doi: 10.1007/s10637-017-0514-4. Epub 2017 Sep 30. Invest New Drugs. 2018. PMID: 28965185 Clinical Trial.
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, Wesson R, Reyad A, Naqvi FF, Ostrander D, Sugarman J, Segev DL, Sulkowski M, Desai NM. Durand CM, et al. Ann Intern Med. 2018 Apr 17;168(8):533-540. doi: 10.7326/M17-2871. Epub 2018 Mar 6. Ann Intern Med. 2018. PMID: 29507971 Free PMC article. Clinical Trial.
9,180 results
Jump to page
Feedback